Zobrazeno 1 - 10
of 24
pro vyhledávání: '"A. S. Olshanskaya"'
Autor:
A. D. Koltakova, A. M. Lila, O. G. Alekseeva, A. A. Fedenko, Y. V. Gridneva, A. S. Olshanskaya
Publikováno v:
Современная ревматология, Vol 16, Iss 5, Pp 46-52 (2022)
Objective: to describe musculoskeletal immune-mediated adverse events (iAEs) associated with the therapy of solid tumors with immune checkpoint inhibitors (ICIs, inhibitors of the PD-1/PD-L1 pathway).Patients and methods. 13 patients receiving ICIs t
Externí odkaz:
https://doaj.org/article/b651571d2d7d46de90e558bff186e959
Autor:
D. A. Khochenkov, M. I. Volkova, I. V. Timofeev, A. S. Olshanskaya, Yu. A. Khochenkova, E. Sh. Solomko, S. A. Ashuba, V. B. Matveev
Publikováno v:
Сибирский онкологический журнал, Vol 20, Iss 4, Pp 64-72 (2021)
Purpose: to study the expression of vascular endothelial growth factor (vegf-a) and its receptors (vegfr-1 and vegfr-2) in renal cell carcinoma (rcc) cells and assess the effect of the expression levels of these markers on the tumor characteristics a
Externí odkaz:
https://doaj.org/article/e766d839f4ab44a8afc121bf20a6ba39
Publikováno v:
Русский журнал детской неврологии, Vol 14, Iss 2, Pp 35-41 (2019)
The authors presented short review of Russian and foreign literature and clinical case of the girl with a rare monogenic disease Cohen syndrome and early infantile epileptic encephalopathy. Problems of differential diagnosis of Cohen syndrome with ot
Externí odkaz:
https://doaj.org/article/4b4924793d614a87b66c6ad292b2e476
Publikováno v:
Медицинский совет, Vol 0, Iss 10, Pp 146-154 (2019)
Cabazitaxel, an antineoplastic agent from the third generation taxan group, has demonstrated efficacy in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. This article is devoted to a critical analysis
Externí odkaz:
https://doaj.org/article/1527490782a441c1bbbc453addb0ed59
Autor:
M. I. Volkova, A. S. Olshanskaya
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 90-94 (2018)
Pazopanib is an oral multitargeted tyrozine kinase inhibitor that is used in advanced renal cancer in most countries of the world. Pazopanib inhibits tyrosine kinase receptors involved in tumor angiogenesis and proliferation, including VEGF, platelet
Externí odkaz:
https://doaj.org/article/857487b459a64fa79fbf8a415a41bb06
Autor:
A. S. Olshanskaya, N. A. Shnayder, D. V. Dmitrienko, O. Yu. Тruneva, E. V. Kozina, S. N. Lanin, S. S. Ilyenkov, Yu. A. Dykhno
Publikováno v:
Сибирский онкологический журнал, Vol 16, Iss 6, Pp 93-99 (2017)
Astrocytic retinal hamartoma (phacoma, astrocytoma) is a benign tumor, formed through proliferation of glial astrocytes and blood vessels of the sensory part of the retina. For the first time, eye involvement in tuberous sclerosis (TS) was described
Externí odkaz:
https://doaj.org/article/12c27c6efc7f4a95941ae75c1e428bae
Autor:
Yu. G. Alyayev, Yu. A. Efimova, G. M. Kuz’micheva, I. Yu. Lovchinovskiy, A. S. Olshanskaya, E. V. Filosofova, L. M. Rapoport, V. I. Rudenko
Publikováno v:
Тонкие химические технологии, Vol 1, Iss 5, Pp 87-99 (2006)
Study of urinary stones of surgical removal has been fulfiled by complex methods. Information of phase and element composition have been received, microstructural examination has been made, causes of anomalous hardness of some stones have been found.
Externí odkaz:
https://doaj.org/article/1492d29bebf24d8cbbbdeea4824cc6c3
Autor:
M. I. Volkova, A. S. Kalpinskiy, P. S. Borisov, O. I. Evsyukova, A. S. Olshanskaya, V. B. Matveev, B. Ya. Alekseev, E. V. Peganova, A. F. Nasretdinov, E. V. Lymar, E. G. Ovchinnikova, T. A. Sveklina, E. A. Usynin, A. M. Abdelgafur, E. A. Tararova, L. M. Shumova, A. S. Belenkov, I. Yu. Dolgov, N. G. Ponomareva, I. V. Evstigneeva, A. N. Ivanov, A. R. Isaev, R. V. Leonenkov, A. V. Meskikh, M. R. Mukhitova, S. A. Orlova, I. V. Teslenok, M. M. Shegurova, M. T. Aivazov, Z. V. Amoev, K. G. Babina, A. A. Vorontsova, E. V. Karabina, N. V. Kirdakova, I. E. Shumskaya, G. P. Kolesnikov, E. S. Kuzmina, D. Kh. Latipova, E. S. Lyutova, M. M. Fael, A. N Chugarova, A. S. Antipin
Publikováno v:
Onkourologiâ, Vol 17, Iss 1, Pp 31-44 (2021)
Objective. The primary endpoint was progression-free survival; secondary endpoints included overall survival, objective response rate and duration, tumor control rate and duration, as well as safety profile of lenvatinib with everolimus in consecutiv
Publikováno v:
Onkourologiâ, Vol 17, Iss 1, Pp 108-119 (2021)
This article analyzes first results of the randomized phase III clinical trial CheckMate 274 that has demonstrated the advantage of adjuvant immunotherapy with nivolumab, a PD-1 inhibitor, over placebo in high-risk patients with muscle-invasive uroth
Autor:
M. I. Volkova, A. S. Olshanskaya, I. V. Tsimafeyeu, N. L. Vashakmadze, Yu. A. Khochenkova, E. Sh. Solomko, S. A. Ashuba, D. A. Khochenkov, V. B. Matveev
Publikováno v:
Onkourologiâ, Vol 16, Iss 1, Pp 17-26 (2020)
Objective: to assess the expression and prognostic value of vascular endothelial growth factor A (VEGF-A), fibroblast growth factor 2 (FGF-2) and their receptors VEGFR-1, -2; FGFR-1, -2, as well as platelet-derived growth factor receptors (PDGFR-α,